Survival rate of thyroid cancer in the Asian countries: a systematic review and meta-analysis study

Endocrine. 2023 Nov;82(2):237-249. doi: 10.1007/s12020-023-03408-5. Epub 2023 Jun 3.


Purpose: Overall, thyroid cancer is the most common endocrine malignancy. This cancer is fifth most common cancer among adult women and the second most common cancer in women over 50 years old and it occurs in women 3 times more than men. The present systematic review and meta-analysis were designed with the aim of determining the 5-year survival rate of thyroid cancer in Asian countries in 2022.

Methods: The current study is a systematic review and meta-analysis of thyroid cancer survival rates in Asian countries. Researchers in the study searched for articles published in six international databases: PubMed/Medline, EMBASE, Scopus, Google Scholar, ISI (Web of Knowledge), and ProQuest until July 03, 2022. A checklist (The Newcastle-Ottawa Quality Assessment Form) has been prepared in previous studies to evaluate the quality of articles.

Results: In general, 38 articles were entered for the meta-analysis. The 5-year survival rate was 95.3%, with a 95% confidence interval of 93.5% to 96.6%. The year of study is a cause of variability in results of 5-year (Reg Coef = 0.145, P < 0.001). According to the results, an increased survival rate across the study period was observed. Human Development Index was a cause of variability in results of 5-year survival rates (Reg Coef = 12.420, P < 0.001). The results of Table 2 showed that women have 4% more 5-year survival rate than men (Hazard ratio: 1.05 CI: 95% 1.04-1.06)).

Conclusion: In general, the 5-year survival of thyroid cancer in Asian countries was higher than in European countries, but it is at a lower level than in the United States.

Keywords: Asia; Meta-Analysis; Survival Rate; Thyroid Neoplasms.

Publication types

  • Meta-Analysis
  • Systematic Review

MeSH terms

  • Adult
  • Asia / epidemiology
  • Endocrine Gland Neoplasms*
  • Europe
  • Female
  • Humans
  • Male
  • Middle Aged
  • Survival Rate
  • Thyroid Neoplasms*